Crypto treasury strategies are increasing: They will acquire the altcoin that is gaining interest.

The biotechnology firm Sonnet BioTherapeutics, which is traded on the Nasdaq exchange, and Rorschach I LLC, a company affiliated with Paradigm, have made the decision to merge. The two companies will merge and develop a HYPE token treasury strategy. The name of the newly formed company will also be Hyperliquid Strategies.

Interest is growing recently

Hyperliquid, a decentralized crypto futures exchange, has attracted significant attention from the crypto world in recent months. The platform's own token, HYPE, has also seen an increase of over 200% in the last 3 months. Additionally, the Hyperliquid exchange has generated over $1.5 trillion in trading volume in the past year.

The giants of crypto are providing support

Companies well-known in the crypto world are also supporting this merger and subsequent operations. Paradigm, Galaxy Digital, Pantera Capital, D1 Capital, Republic Digital, and 683 Capital will invest in the newly formed company, which will be named Hyperliquid Strategies.

"Corporate interest is very high..."

Matt Huang, the founder of Paradigm among these companies, stated that Hyperliquid has recently attracted the interest of institutional investors and said, "Hyperliquid stands out with its fundamental underpinnings and strong participants. There is a lot of institutional interest. However, access to the HYPE token is not easy for institutions in the US. We want to facilitate this."

The new company is expected to have $305 million in cash along with 12.5 million HYPE after the merger. Additional HYPE token purchases will be made with the extra cash obtained later.

At the end of November, the Hyperliquid exchange, which entered the crypto world, has seen an increase of over 600% since then with its own token HYPE.

Published: July 14, 2025 16:16Last Updated: July 14, 2025 16:23